We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In this article, we will discuss the 10 Best Stocks to Buy According to Billionaire David Einhorn. David Einhorn is a highly ...

Roivant Sciences Ltd. has a 52-week low of $9.80 and a 52-week high of $13.06. Roivant Sciences ( NASDAQ:ROIV – Get Free Report ) last posted its quarterly earnings results on Monday, February 10th.

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Roivant Sciences ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...